INS and diabetes mellitus: In newly diagnosed DM type 2 patients with ACS who refuse to take insulin, an anti‐DM regimen consisting of multiple oral agents is a safe and effective alternative and can lead to a comparable reduction in hbA1c at 1‐year follow‐up without a concomitant increase in the risk of acute hyperglycaemic events and recurrent admission due to cardiac reasons.